Oramed Pharmaceuticals Inc.
ORMP
Last
$4.33
Day
+3.1%
1y
+98.1%
5y
-79.0%
52w
-23.2%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1233d
EMA 21
4.55
EMA 50
4.56
EMA 200
3.94
20d high
-14.3%
5y high
-86.6%
5y range
9th
Positions held
Your positionsORMP isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-16
Hold
avoid
Signal
Strong Sell
Target
$4.49
Stop
$3.95
Stop distance
8.8%
Target vs last
+3.7%
Fundamentals
| Market cap | $174.71M | Enterprise value | $124.83M | Trailing P/E | 1.02 | Forward P/E | -52.50 |
| PEG | — | Price / book | 0.55 | Beta | 1.28 | Dividend yield | 5.92% |
| Revenue growth | — | Earnings growth | 493.5% | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | 74.2% | ROA | -3.4% | Debt / equity | 0.00 |
| Current ratio | 4.98 | Free cash flow | $2.51M | Analyst recommendation | none | Mean target | $7.00 |
| 52w high | $5.47 | 52w low | $2.09 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | $78.2M | $38.3M | $10.0M | $48.4M | $13.3M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Operating income | -$2.8M | -$3.7M | -$5.7M | -$2.4M | -$2.5M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $2.0M | $0.0M | $1.3M | $2.7M |
| Op margin | -754.4% | — | -1176.8% | -1502.0% |
| Net income | $64.0M | -$19.1M | $5.5M | -$36.6M |
| Gross margin | 0.7% | — | — | — |
| Gross profit | $0.0M | $0.0M | — | — |
| Operating income | -$15.1M | -$12.8M | -$15.8M | -$40.6M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-08 · Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
2026-08-31 · Lifeward Names Josh Hexter as Interim CEO and Rami Aviram as CFO
2026-08-28 · ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness
2026-08-17 · Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee
2026-08-10 · Oramed: Q2 Earnings Snapshot
Price (daily)
Full chart · RSI · MACD · patternsORMP · daily-11.6% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin